Blue Lotus
Comparing r2 → r2.a4+10,178bytes
Article Changes3 modified · 7 added · 26 unchanged
* Nuciferine acts on serotonin and dopamine systems; blocking certain serotonin receptors reduces perceptual distortion risk, and partial dopamine receptor activation with slowed reuptake contributes to mild mood lift and sedation{{cite|doi=10.1371/journal.pone.0150602|anchor=7cb9c3d3}}
* In animal models, nuciferine resembled clozapine — an atypical antipsychotic — in behavioral tests, without producing muscle stiffness{{cite|doi=10.1371/journal.pone.0150602|anchor=e9b2abe2}}
* Extract from related ''Nymphaea lotus'' extended sleep duration in mice, consistent with GABA receptor involvement{{cite|pubmed=29881419|anchor=e5c5d78a}}
* Nuciferine crosses the blood-brain barrier{{cite|doi=10.1016/j.jchromb.2014.04.038|anchor=ce7bbb48}}
* Related lotus plants inhibit liver enzymes that process certain medications{{cite|doi=10.1016/j.jep.2014.02.014|anchor=321e22bd}}
* Open: no neuroimaging studies with ''N. caerulea'' have been published; nuciferine concentrations achieved by human preparations are unknown{{cite|name=mitra-2022-nelumbo|type=web|author=Mitra K et al.|year=2022|title=Therapeutic Potential of Nelumbo nucifera in CNS Disorders|anchor=19b0e597}}
| Common form | Dried flowers, pre-rolled blends, tinctures, concentrated resins, and vape cartridges; none carry verified alkaloid content labeling |
| Look-alike risk | Effects inconsistent with mild sedation — especially rapid-onset intense euphoria, strong dissociation, or acute anxiety — warrant immediate discontinuation; synthetic cannabinoid contamination is a documented risk |
| Test | Standard reagent kits and [[substance:fentanyl|fentanyl]] test strips cannot detect blue lotus alkaloids or synthetic cannabinoid contaminants; laboratory LC-MS/MS or GC-MS is the only reliable method to confirm species identity and screen for adulterants |
| Set and setting | Calm, low-demand environments; oneirogenic effects most pronounced in pre-sleep settings; do not operate vehicles or machinery after use; avoid combining with [[substance:alcohol|alcohol]], which adds unpredictable sedation |
| Plan for | For a first experience with any inhaled preparation, have a sober companion present; vaporized products are faster and less predictable than oral ones |
| Seek help if | Severe confusion or unresponsiveness; chest pain or rapid heartbeat; seizure activity; intense paranoia, panic, or psychotic symptoms; breathing difficulty |
| Immediate steps | Do not leave the person alone; if unconscious or seizing, place in the recovery position; call emergency services if symptoms include seizure, chest pain, loss of consciousness, or breathing difficulty; do not induce vomiting |
| Afterwards | Post-experience grogginess or residual sedation is common; hydrate and eat a light meal after effects resolve |
| Clinical era | Western clinical reporting began in 2017 with cases involving blue lotus resin in electronic cigarettes{{cite|doi=10.1080/02791072.2017.1290304|anchor=7abfb8b0}} |
| Traditional use | Documented religious use in ancient Egypt for over two millennia, traced to approximately 2500 BCE{{cite|doi=10.3390/rel9090256|anchor=ce585e95}} |
| Tolerance onset | No published data on tolerance development in humans{{flag|safety-citation-needed}} |
| Mechanism | Nuciferine's partial action on dopamine receptors raises a theoretical possibility of tolerance with repeated use, analogous to patterns with other dopamine partial agonists{{flag|inferred}} |
| Physical dependence | No case reports of blue lotus dependence published{{flag|safety-citation-needed}} |
| Withdrawal | No case reports of blue lotus withdrawal published{{flag|safety-citation-needed}} |
| Psychological dependence | No formal dependence documented; habitual use of any psychoactive substance warrants self-assessment |
| Escalating use | If use has become daily or near-daily, or if sleep without it has become difficult, consider reducing frequency before stopping entirely |
| Character | Gentle sedative-oneirogenic experience; dream-like quality strongest in pre-sleep contexts and varies substantially with set and setting |
| Common | Mild relaxation, reduced anxiety, and quiet well-being; most prominent via oral preparation |
| Dose-dependent | Higher doses and inhaled routes shift the experience toward perceptual changes and vivid hypnagogic imagery |
=== Toxicity ===
=== Psychological risks ===
=== Interactions ===
=== Contraindications ===
| Lethal dose | No LD50 or formal acute toxicity data exist for ''N. caerulea'' or its preparations{{flag|safety-citation-needed}} |
| Confirmed deaths | None attributed to ''N. caerulea'' alone identified in published literature |
| Heart | Chest pain and rapid heartbeat documented in DoD adverse event data{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=b86f6374}} |
| Controlled studies | Single case-series: five military patients developed altered mental status, all recovering with supportive care{{cite|doi=10.1093/milmed/usab328|anchor=c15f7b54}} |
| Psychosis | No published data on precipitation of psychotic episodes in vulnerable individuals; receptor profile theoretically suggests lower risk than classical psychedelics{{cite|doi=10.1371/journal.pone.0150602|anchor=096a9ead}} |
| Other | Confusion, hallucinations, and paranoia possible at high doses and via inhaled preparations{{cite|doi=10.1093/milmed/usab328|anchor=e398dd88}}{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=7f0cb589}} |
| Dangerous | Benzodiazepines — additive sedation expected given nuciferine's sedative properties{{flag|safety-citation-needed}} |
| Dangerous | MAOIs — could amplify monoamine-related effects of blue lotus alkaloids; historically combined in ritual preparations{{cite|doi=10.1038/s41598-024-78721-8|anchor=d5815b9c}}{{flag|safety-citation-needed}} |
| Dangerous | Opioids — additive sedation expected given nuciferine's sedative properties{{flag|safety-citation-needed}} |
| Dangerous | SNRIs — nuciferine's dopamine and serotonin activity raises theoretical concern in combination{{flag|safety-citation-needed}} |
| Dangerous | SSRIs — nuciferine's dopamine and serotonin activity raises theoretical concern in combination{{flag|safety-citation-needed}} |
| Caution | Atypical antipsychotics — nuciferine shares dopamine and serotonin receptor targets with antipsychotics; could augment or disrupt antipsychotic dosing{{flag|safety-citation-needed}} |
| Absolute | Pregnancy and lactation — no published safety data{{flag|safety-citation-needed}} |
| Relative | Psychiatric conditions (dopamine and serotonin receptor activity); cardiovascular disease (chest pain and tachycardia documented{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=23850179}}); seizure disorders (at least one seizure documented{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=3a1aac6c}}); hepatic impairment (potential CYP inhibition{{flag|safety-citation-needed}}); U.S. military service (prohibited on and off duty{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=7b9475aa}}) |
| International | Not scheduled under any major international drug treaty; neither nuciferine nor apomorphine internationally controlled{{cite|name=erowid-lotus-legal|type=web|author=Erowid.org|year=2016|title=Erowid Lotus Legal Status|anchor=8764fea2}} |
| United States | Unscheduled under federal law; FDA has not approved for human consumption; cannot legally be marketed as a dietary supplement{{cite|name=erowid-lotus-legal|type=web|author=Erowid.org|year=2016|title=Erowid Lotus Legal Status|anchor=aa8e56f6}} |
| Louisiana | Banned for human consumption since 2005{{cite|name=erowid-lotus-legal|type=web|author=Erowid.org|year=2016|title=Erowid Lotus Legal Status|anchor=d77481ed}} |
| U.S. military | All personnel prohibited from use on or off duty{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=532609d7}} |
| Russia | Scheduled in 2009{{cite|name=lotus-extracts-legal|type=web|author=Lotus-Extracts.com|year=2024|title=International legal status of blue lotus|anchor=5c81bbc4}} |
| Poland | Scheduled in 2009{{cite|name=lotus-extracts-legal|type=web|author=Lotus-Extracts.com|year=2024|title=International legal status of blue lotus|anchor=24715943}} |
| Latvia | Classifies as a controlled substance{{cite|name=lotus-extracts-legal|type=web|author=Lotus-Extracts.com|year=2024|title=International legal status of blue lotus|anchor=e7f8f04d}} |
| United Kingdom | Currently permitted{{flag|citation-needed}} |
| Canada | Currently permitted{{flag|citation-needed}} |
| Germany | Currently permitted{{flag|citation-needed}} |
| Netherlands | Currently permitted{{flag|citation-needed}} |
| Australia | Currently permitted{{cite|name=erowid-lotus-legal|type=web|author=Erowid.org|year=2016|title=Erowid Lotus Legal Status|anchor=eeed1521}} |
[[substance:blue-lotus|Blue lotus]] produces a characteristically gentle [[substance_class:psychoactive/sedative|sedative]]-oneirogenic experience. At lower doses, oral preparations bring mild relaxation, reduced [[effect:anxiety|anxiety]], and quiet well-being. At higher doses or via inhaled routes, the experience shifts toward perceptual changes and vivid hypnagogic imagery — the dream-like quality the plant is best known for. This dimension is strongest in pre-sleep contexts and varies substantially with [[glossary:set-and-setting|set and setting]].
The experience occupies a distinct niche. Nuciferine's [[glossary:receptor|receptor]] profile is closer to an atypical [[substance_class:psychoactive/antipsychotic|antipsychotic]] than to a classical sedative or [[substance_class:chemical/benzodiazepine|benzodiazepine]], yet at typical doses the character more closely resembles a mild [[substance_class:psychoactive/anxiolytic|anxiolytic]] tea with dream-enhancing [[glossary:aftereffect|aftereffects]]. Vaporized preparations differ meaningfully from oral ones — faster onset, a higher [[glossary:intensity|intensity]] ceiling, and less predictable effects. Because commercial products frequently lack authentic [[glossary:plant-material|plant material]], actual experiences may not reflect what genuine ''N. caerulea'' pharmacology predicts.
[[substance:blue-lotus|Blue lotus]] produces a characteristically gentle [[substance_class:psychoactive/sedative|sedative]]-oneirogenic experience. At lower doses, oral preparations yield mild relaxation, [[effect:anxiety-suppression|anxiolysis]], and a sense of well-being; at higher doses or via inhaled routes, perceptual shifts and vivid hypnagogic imagery emerge. The oneirogenic quality — enhanced dream vividness and liminal-state imagery — is the defining experiential signature, most consistently reported in pre-sleep contexts. [[glossary:set-and-setting|Set and setting]] modulate this dimension substantially, and preparation method determines both onset speed and [[glossary:intensity|intensity]] ceiling.
The experience occupies a pharmacological niche distinct from classical sedative-[[substance_class:psychoactive/hypnotic|hypnotics]]. Nuciferine's [[glossary:receptor|receptor]] profile positions it closer to atypical [[substance_class:psychoactive/antipsychotic|antipsychotics]] than to [[substance_class:chemical/benzodiazepine|benzodiazepines]], yet at typical doses the subjective character more closely resembles a mild [[substance_class:psychoactive/anxiolytic|anxiolytic]] tea with dream-enhancing [[glossary:aftereffect|aftereffects]] than any clinical antipsychotic experience. The significant product [[glossary:adulterant|adulteration]] risk means that the actual experience of any given commercial product may not reflect the pharmacology of authentic ''N. caerulea''.
[[substance:blue-lotus|Blue lotus]] preparations produce a characteristically [[substance_class:psychoactive/sedative|sedative]]-oneirogenic experience whose qualitative character depends strongly on preparation method and — critically — product authenticity. Vaporized resin or extract produces rapid, more pronounced effects including perceptual [[glossary:disturbance|disturbances]] and altered mental status, while oral preparations (tea, infused wine) yield gentler [[effect:sedation|sedation]] with reported [[substance_class:psychoactive/anxiolytic|anxiolytic]] and mildly euphoric qualities. [[glossary:set-and-setting|Set and setting]] modulate the oneirogenic dimension; dream-enhancing properties are most consistently reported in pre-sleep contexts. The significant product [[glossary:adulterant|adulteration]] risk means that the actual experience of any given commercial product may not reflect the pharmacology of authentic ''N. caerulea''.
Blue lotus occupies a pharmacological niche distinct from classical sedative-[[substance_class:psychoactive/hypnotic|hypnotics]]. Nuciferine's [[glossary:receptor|receptor]] profile — combining [[glossary:5-ht2a|5-HT2A]] [[glossary:antagonism|antagonism]] with D2 partial agonism and [[glossary:dopamine-transporter|DAT]] [[glossary:inhibition|inhibition]] — positions it closer to atypical [[substance_class:psychoactive/antipsychotic|antipsychotics]] than to [[substance_class:chemical/benzodiazepine|benzodiazepines]] or antihistamines, though at commonly reported doses the [[glossary:subjective-experience|subjective experience]] more closely resembles a mild sedative-anxiolytic with oneirogenic qualities than a clinical antipsychotic effect.